Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
The Oncologist|November 15, 2017
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant GliomaAshley Ghiaseddin, David Reardon, Woody Massey, et al.
Seminars in Oncology Nursing|November 10, 2018
Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade GliomaMary Lou Affronti, Dina Randazzo, Eric S Lipp, et al.
Journal of Neuropathology and Experimental Neurology|December 1, 2018
MGMT: Immunohistochemical Detection in High-Grade AstrocytomasEric S Lipp, Patrick Healy, Alan Austin, et al.
Health Science Reports|May 4, 2019
Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practiceAnnick Desjardins, James E Herndon, Frances McSherry, et al.
Frontiers in Oncology|March 18, 2021
Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution AnalysisJessica W Lee, John P Kirkpatrick, Frances McSherry, et al.
Nuclear Medicine and Biology|October 1, 2011
Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptorsMichael R Zalutsky, Abraham Boskovitz, Chien-Tsun Kuan, et al.
Cancer Medicine|May 2, 2013
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastomaEmil Lou, Katherine B Peters, Ashley L Sumrall, et al.
BMC Cancer|September 3, 2010
MRP3: a molecular target for human glioblastoma multiforme immunotherapyChien-Tsun Kuan, Kenji Wakiya, James E Herndon, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 24, 2019
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomideMallika P Patel, Sarah Woodring, Dina M Randazzo, et al.
Neuro-Oncology Practice|August 15, 2025
Phase II randomized glioma study to evaluate efficacy and satisfaction of rolapitant plus ondansetron in preventing chemoradiation-induced nausea and vomitingMary Lou Affronti, Mallika P Patel, Erin K Severance, et al.
Pageof 4